Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.
No interventions are planned.

Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.
No interventions are planned.

Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.
no interventions are planned.

Plasma, serum, PBMC, whole blood, urine. There is a possibility of DNA extraction from PBMC

Diabetes Complications

No interventions are planned for this study, it is purely observational.

No interventions are planned for this study.

Department of Medicine, University of Heidelberg

Heidelberg Study on Diabetes and Complications

Diabetic complications include diabetic nephropathy, diabetic retinopathy, diabetic polyneuropathy, autonomous neuropathy, or macrovascular complications such as stroke, peripheral artery disease, or myocardial infarction.

No sharing of individual participant data is planned.

Stefan Kopf MD

Head of the Clinical Study Center for Diabetes Research

Heidelberg University

Samples of the LE (Lupus Erythematosus) group from a specimen collection : "Lupus BioBanque du Rhin Supérieur" (LBBR UF 9882).
It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank "Lupus BioBanque du Rhin Supérieur" (project : LBBR UF 9882).

Lupus Erythematosus

Chu de Reims

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

CHU de Reims

Presence of malnutrition will be assessed by using the Subjective Global Assessment.
Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters.

Chronic Kidney Disease

Derby Hospitals NHS Foundation Trust

Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.

Association of Advanced Glycation End-product Accumulation and Adverse Outcomes in Peritoneal Dialysis and Haemodialysis Patients and the Impact of a Dietetic Intervention on Skin Autofluorescence

Association of increased skin autofluorescence (SAF) levels with mortality/one year survival

Study 1: Mean change in SAF levels from baseline to 12 months of follow-up
Study 2: Mean change in SAF levels after 6 months of a dietetic intervention (i.e. intensive dietetic supervised nutritional support)

Pearson correlation between SAF levels with serum levels of haemoglobin, albumin and total proteins (unit of measure: g/L) at baseline and every month, until 12 months of follow-up.

Pearson correlation between SAF levels with percentage of haemoglobin A1C at baseline and every month, until 12 months of follow-up.

Pearson correlation between SAF levels with serum levels of glucose, urea, potassium, phosphate, calcium, sodium, cholesterol and triglycerides (unit of measure: mmol/L) at baseline and every month, until 12 months of follow-up.

Pearson correlation between SAF levels with serum levels of creatinine (unit of measure: µmol/L) at baseline and every month, until 12 months of follow-up.

Pearson correlation between SAF levels with serum levels of intact parathyroid hormone (unit of measure: pmol/L) at baseline and every month, until 12 months of follow-up.

Pearson correlation between SAF levels with serum levels of carboxymethyl lysine (unit of measure: ng/mL) at baseline, 3rd, 6th, 9th and 12th month of follow-up.

Pearson correlation between SAF levels with serum levels of C reactive protein (unit of measure: mg/L) at baseline, 3rd, 6th, 9th and 12th month of follow-up.

Pearson correlation between SAF levels with serum levels of tumour necrosis factor-α and interleukin-6 (unit of measure: pg/mL) at baseline, 3rd, 6th, 9th and 12th month of follow-up.

Pearson correlation between SAF levels with energy intake (unit of measure: kcal/day) estimated from a 24-h dietary recall, at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with protein intake (unit of measure: g/day) estimated from a 24-h dietary recall, at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with dietary AGE intake (unit of measure: Equivalents/day), estimated from a database of ~560 foods which listed AGE values, at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with number of patients classified as well-nourished, at risk of malnutrition/moderate malnutrition or malnourished according with the Subjective Global Assessment score, at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with dry weight and handgrip strength (unit of measure: kg), at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with body mass index (unit of measure: kg/m2), at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with mid-arm circumference (unit of measure: cm), at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with triceps and subscapular skinfold thickness (unit of measure: mm), at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with mid-arm muscle and fat areas (unit of measure: cm2), at baseline, 6th and 12th month of follow-up.

Pearson correlation between SAF levels with quality of life score obtained from the EQ-5D and SF-36 questionnaires, at baseline, 6th and 12th month of follow-up.

Monthly changes in serum levels of haemoglobin, albumin and total proteins (unit of measure: g/L) after the dietetic intervention.

Monthly change in percentage of haemoglobin A1C after the dietetic intervention.

Monthly changes in serum levels of glucose, urea, potassium, phosphate, calcium, sodium, cholesterol and triglycerides (unit of measure: mmol/L) after the dietetic intervention.

Monthly change in serum levels of creatinine (unit of measure: µmol/L) after the dietetic intervention.

Monthly change in serum levels of intact parathyroid hormone (unit of measure: pmol/L) after the dietetic intervention.

Change in serum levels of carboxymethyl lysine (unit of measure: ng/mL) after the dietetic intervention, from baseline to 3rd and 6th months.

Change in serum levels of C reactive protein (unit of measure: mg/L) after the dietetic intervention, from baseline to 3rd and 6th months.

Change in serum levels of tumour necrosis factor-α and interleukin-6 (unit of measure: pg/mL) after the dietetic intervention, from baseline to 3rd and 6th months.

Change in energy intake (unit of measure: kcal/day) estimated from a 24-h dietary recall after 6 months of the dietetic intervention

Change in protein intake (unit of measure: g/day) estimated from a 24-h dietary recall after 6 months of the dietetic intervention

Change in dietary AGE intake (unit of measure: Equivalents/day), estimated from a database of ~560 foods which listed AGE values after 6 months of the dietetic intervention.

Change in number of patients classified as well-nourished, at risk of malnutrition/moderate malnutrition or malnourished according with the Subjective Global Assessment score after 6 months of the dietetic intervention.

Change in dry weight and handgrip strength (unit of measure: kg) after 6 months of the dietetic intervention.

Change in body mass index (unit of measure: kg/m2) after 6 months of the dietetic intervention.

Change in mid-arm circumference (unit of measure: cm) after 6 months of the dietetic intervention.

Change in triceps and subscapular skinfold thickness (unit of measure: mm) after 6 months of the dietetic intervention.

Change in mid-arm muscle and fat areas (unit of measure: cm2) after 6 months of the dietetic intervention.

Change in quality of life score obtained from the EQ-5D and SF-36 questionnaires after 6 months of the dietetic intervention.

University of Nottingham

University Hospitals of Derby and Burton NHS Foundation Trust

The Haptoglobin 2-2 group randomised to Vitamin E

The Haptoglobin 2-2 group randomised to placebo

The Non Haptoglobin 2-2 group randomised to Vitamin E

The Non Haptoglobin 2-2 group randomised to placebo

Diabetes Mellitus

Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Vitamin E

Placebo

Tan Tock Seng Hospital

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Measured as Reactive hyperemia index using RHI-EndoPAT

Measured as pulse wave velocity using the sphygmocor device

Measured as ratio between retinal arterial diameter and venous diameter as retinal AV index

glyoxal/infiammazione

Heidelberg Study on Diabetes and Complications

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Il database di erbe medicinali più completo supportato dalla scienza